TICKERNOMICS Sign up
Last Update: 2024-03-28 02:15:54
Jaguar Health Inc. ( JAGX ) https://jaguar.health
0.07USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
31.15%
-91.15%
JAGX
SPY
32.74%
-99.98%
JAGX
SPY
92.93%
-100.00%
JAGX
SPY
224.41%
JAGX
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
1.50
37.85
41.44
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-0.04
0.14
1.06
-2377.67
0.00
-1.14
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-312.37
81.73
-322.62
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
6.0977
-102.01
-140.49
0.49
Other Earnings and Cash Flow Stats:
Jaguar Health Inc. ( JAGX ) Net Income TTM ($MM) is -39.88
Jaguar Health Inc. ( JAGX ) Operating Income TTM ($MM) is -34.81
Jaguar Health Inc. ( JAGX ) Owners' Earnings Annual ($MM) is -32.88
Jaguar Health Inc. ( JAGX ) Current Price to Owners' Earnings ratio is -0.04
Jaguar Health Inc. ( JAGX ) EBITDA TTM ($MM) is -31.29
Jaguar Health Inc. ( JAGX ) EBITDA Margin is -322.62%
Capital Allocation:
Jaguar Health Inc. ( JAGX ) has paid 0.00 dividends per share and bought back -19.394312 million shares in the past 12 months
Jaguar Health Inc. ( JAGX ) has reduced its debt by 11.623 million USD in the last 12 months
Capital Structure:
Jaguar Health Inc. ( JAGX ) Interest-bearing Debt ($MM) as of last quarter is 39
Jaguar Health Inc. ( JAGX ) Annual Working Capital Investments ($MM) are 17
Jaguar Health Inc. ( JAGX ) Book Value ($MM) as of last quarter is 1
Jaguar Health Inc. ( JAGX ) Debt/Capital as of last quarter is 2910%
Other Balance Sheet Stats:
Jaguar Health Inc. ( JAGX ) has 3 million in cash on hand as of last quarter
Jaguar Health Inc. ( JAGX ) has 12 million of liabilities due within 12 months, and long term debt 34 as of last quarter
Jaguar Health Inc. ( JAGX ) has 20 common shares outstanding as of last quarter
Jaguar Health Inc. ( JAGX ) has 0 million USD of preferred stock value
Academic Scores:
Jaguar Health Inc. ( JAGX ) Altman Z-Score is -11.31 as of last quarter
Jaguar Health Inc. ( JAGX ) Piotroski Score is 3.00 as of last quarter
Corporate Governance:
Jaguar Health Inc. ( JAGX ) largest shareholder is owning shares at 0.00 ($MM) value
Wolin Jonathan S.(Chief of Staff, CCO & GC) Bought 196018 shares of Jaguar Health Inc. ( JAGX ) for the amount of $0.00 on 2022-03-28
17.67% of Jaguar Health Inc. ( JAGX ) is held by insiders, and 2.05% is held by institutions
Jaguar Health Inc. ( JAGX ) went public on 2015-05-13
Other Jaguar Health Inc. ( JAGX ) financial metrics:
FCF:-32.83
Unlevered Free Cash Flow:-52.05
EPS:-1.50
Operating Margin:-312.37
Gross Profit Margin:81.73
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-2287.65
Beta:0.49
Buffet's Owners Earnings:-32.88
Price to Owner's Earnings:-0.04
About Jaguar Health Inc. ( JAGX ) :
Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing preion medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including Short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops NP-300, a second-generation proprietary anti-secretory antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. The company was founded in 2013 and is headquartered in San Francisco, California.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.